Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2024 07:30 ET | Source: Sanofi - Aventis Groupe

Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn Les...
October 29, 2024 11:30 ET | Source: Future Market Insights Global and Consulting Pvt. Ltd.

Demand For Innovative Therapies for Chronic Illnesses is set to Drive Growth in the Biologics Market is projected to reach USD 817.48 Billion by 2032, growing at a CAGR of 8.5% | FMI

NEWARK, Del, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The global biologics market, valued at USD 335.43 billion in 2021, is anticipated to soar to USD 817.48 billion by 2032, expanding at an impressive...
September 26, 2024 02:30 ET | Source: Abivax

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and...
July 08, 2024 08:00 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024

Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.
May 08, 2024 02:30 ET | Source: Abivax

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
April 12, 2024 11:32 ET | Source: Visiongain Reports Ltd

Inflammatory Bowel Diseases (IBD) Drugs market is projected to grow at a CAGR 6.2% by 2034: Visiongain

Visiongain has published a new report entitled Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034: Forecasts by Indication (Crohn's Disease, Ulcerative Colitis), by Route of...
March 05, 2024 03:10 ET | Source: Everzom

Licence exclusive avec Erganeo pour EVerGel, premier candidat médicament d’EVerZom, un traitement révolutionnaire des fistules et de la fibrose du tube digestif.

Licence exclusive avec Erganeo pour EVerGel, premier candidat médicament d’EVerZom, un traitement révolutionnaire des fistules et de la fibrose du tube digestif. Cette nouvelle licence mondiale est...
February 22, 2024 16:01 ET | Source: Galapagos NV

Galapagos kondigt 2023 jaarresultaten en vooruitzichten 2024 aan

Financiële kerngetallen voor het hele jaar 2023: Netto groepsomzet van €783,5 miljoen in 2023, inclusief €112,3 miljoen nettoverkopen voor Jyseleca® Geldmiddelen en kortlopende financiële...
February 22, 2024 07:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)

Results of the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis to be highlighted in oral presentation on February 22nd SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ventyx...
February 08, 2024 08:05 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health SystemFlorian Rieder, MD,...